The rate of HIV infection continues to climb globally. Around 40 million people live with HIV-1, the most common HIV strain. While symptoms can now be better managed with lifelong treatment, there is ...

The tiny shell protecting the HIV virus resembles a slightly rounded ice cream cone, but there is nothing sweet about it. More than 40 million people worldwide live with AIDS because of this virus, ...

University of Virginia School of Medicine scientists have uncovered a key reason why HIV remains so difficult to cure: Their research shows that small changes in the virus affect how quickly or slowly ...

Though Gilead Sciences made waves last June with a landmark FDA approval for its twice-yearly HIV preventive Yeztugo (lenacapavir), the first-in-class drug had previously been used as a long-acting ...

The FDA granted priority review, with a decision expected by June 19, 2025. LEN represents a novel class of HIV therapies by targeting the viral capsid, a multifunctional protein essential for HIV ...

Brown researchers will look into how a drug originally developed to treat HIV may reduce age-related inflammation.

HIV-seq identifies key differences in HIV-infected cells before and after starting antiretroviral therapy to support treatment research.

Long-acting antiviral medications are transforming HIV prevention and care, requiring only minimalistic dosing. But as the use of lenacapavir expands, scientists are probing a critical question: If ...

Gloved fingers hold a labeled vial of lenacapavir, a clear, yellowish liquid. Lenacapavir (shown) is an antiretroviral medication used to help prevent and treat HIV. Credit: Associated Press While ...